How can registries contribute to the development and evaluation of CNS therapeutics?
Joanne B Severe1, Annette Stemhagen
1Ms. Severe is a research consultant in Rockville, Maryland, and Dr. Stemhagen is with United Biosource Corp. in Bethesda, Maryland.
Abstract:
This article is based on the proceedings from a workshop held during the Autumn 2011 International Society for CNS Clinical Trials and Methodology (ISCTM) Conference in Amelia Island, Florida. The goal of the workshop was to establish preliminary steps in determining whether and how patient registries can augment clinical trials in the field of central nervous system therapeutics. Participants in the workshop first defined several different types of registries and then created a list of questions that should be addressed in order to determine how registries might be used. The workshop concluded with discussion on logistical and practical considerations regarding use of patient registries.
Related Concept Videos
Clinical Trials: Overview
Drug Regulation
Preclinical Development: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Therapeutic Drug Monitoring: Overview and Classification
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...


